Clinical Trial Update: A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis. [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating once-monthly ibandronate (Bonviva) for prevention of glucocorticoid-induced osteoporosis has completed, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glucocorticoid-induced Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• Bonviva (ibandronic acid)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Postmenopausal Osteoporosis | Phase 4 | Status: COMPLETED | Results posted: 2016-05-12